United Kingdom· GB-APID-3976511000001102
Virgan 0.15% eye gel
A ganciclovir product containing ganciclovir, registered in United Kingdom by Thea Pharmaceuticals Ltd. The same ATC class is registered in 9 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ganciclovir is registered in 9 of 19 countries.
Countries holding a registration under ATC S01AD09 (ganciclovir), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Ganciclovir · ATC S01AD09
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ganciclovir
- Manufacturer
- Thea Pharmaceuticals Ltd
- Country
- United Kingdom (GB)
- ATC code
- S01AD09
- ATC class
- Ganciclovir
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin3662042000393
- gtin3662042002984
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ganciclovir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandCymeveneInPharm Sp. z o.o.
- United StatesganciclovirSagent Pharmaceuticals
- FinlandCymeveneOrifarm Oy
- SpainCYMEVENE 500 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONCheplapharm Arzneimittel Gmbh
- SwedenCymevene 500 mg Pulver till koncentrat till infusionsvätska, lösningOrifarm AB
- GermanyCymeven I.V.Cheplapharm Arzneimittel Gmbh
- CanadaCYTOVENECHEPLAPHARM ARZNEIMITTEL GMBH
- FranceCYMEVAN 500 mg, poudre pour solution à diluer pour perfusionCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Cymevene, Ganciclovir Oresund Pharma
- Belgium · Cymevene, Virgan
- Bulgaria · Ганцикловир Ромфарм
- Czechia · Cymevene, Virgan
- Germany · Cymeven I.V., Ganciclovir Accord
- Denmark · Cymevene, Ganciclovir Oresund Pharma
- Spain · Cymevene, Ganciclovir Accord
- Finland · Cymevene, Ganciclovir Bioglan
- France · Cymevan, Ganciclovir Hikma
- Greece · Gancilen, Virgan
- Croatia · Cymevene
- Hungary · Cymevene, Ganciclovir Rompharm
- Ireland · Cymevene
- Italy · Citovirax, Ganciclovir Accord
- Luxembourg · Cymevene, Virgan
- Netherlands · Cymevene, Ganciclovir Sandoz
- Norway · Cymevene, Ganciclovir Bioglan
- Poland · Cymevene, Ganciclovir Accord
- Portugal · Cymevene, Ganciclovir Accord
- Romania · Ganciclovir Rompharm, Virgan
- Sweden · Cymevene, Ganciclovir Bioglan
- Slovakia · Cymevene
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc0f2ae8-d76c-483c-af78-a24cd8d1cce1 GET /v1/drugs/dc0f2ae8-d76c-483c-af78-a24cd8d1cce1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "3976511000001102",
"desc": "Virgan 0.15% eye gel (Thea Pharmaceuticals Ltd)",
"form": "Eye gel",
"vpid": "41486411000001100",
"source": "dmd",
"vtm_id": "776081008",
"strength": "1.5 mg",
"substance": "Ganciclovir",
"ingredient": "Ganciclovir",
"supplier_code": "14937811000001101"
}See everything about ganciclovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.